Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

Dhodapkar, Madhav V.; Dhodapkar, Kavita M.

doi:10.3389/fimmu.2019.02385

Cited by 6 publications

(5 citation statements)

References 90 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2018 [8,12] Regarding cancer prevention medicine, breast and colon cancer show the strongest clinical evidence that pharmacological intervention can reduce cancer risk [13]. Recent studies reported that OPMDs are immunogenic, speculating immune-based approaches for targeted cancer prevention [14]. This work aims to analyze the possible use of drugs such as immunochemopreventive agents for OPMDs.…”

Section: Intermittent Dosing Schedulesmentioning

confidence: 99%

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Grigolato

Bizzoca

Calabrese

et al. 2020

IJMS

View full text Add to dashboard Cite

Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations frequently characterized by an architectural and cytological derangements upon histological analysis. Among them, oral leukoplakia is the most common type of these disorders. This work aims to analyze the possible use of drugs such as immunochemopreventive agents for OPMDs. Chemoprevention is the use of synthetic or natural compounds for the reversal, suppression, or prevention of a premalignant lesion conversion to malignant form. Experimental and in vivo data offer us the promise of molecular prevention through immunomodulation; however, currently, there is no evidence for the efficacy of these drugs in the chemoprevention action. Alternative ways to deliver drugs, combined use of molecules with complementary antitumor activities, diet influence, and better definition of individual risk factors must also be considered to reduce toxicity, improve compliance to the protocol treatment and offer a better individualized prevention. In addition, we must carefully reconsider the mode of action of many traditional cancer chemoprevention agents on the immune system, such as enhancing immunosurveillance and reversing the immune evasion. Several studies emphasize the concept of green chemoprevention as an alternative approach to accent healthy lifestyle changes in order to decrease the incidence of HNSCC.

show abstract

Section: Intermittent Dosing Schedulesmentioning

confidence: 99%

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Grigolato

Bizzoca

Calabrese

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Two randomized trials have demonstrated that lenalidomide (alone or with dexamethasone) in patients with SMM can reduce the risk of progression to clinical MM 28,29 . However, the finding that the hierarchy of T‐cell exhaustion/dysfunction is established early on in patients with monoclonal gammopathy suggests the need to consider testing immune‐based prevention approaches even earlier than “high‐risk” SMM 22,30,31 . In this regard, an important aspect of immune biology may be changes in spatial architecture with evolution to MM.…”

Section: Immune Recognition Of Premalignancy and Implications For Pre...mentioning

confidence: 99%

“…28,29 However, the finding that the hierarchy of T-cell exhaustion/dysfunction is established early on in patients with monoclonal gammopathy suggests the need to consider testing immune-based prevention approaches even earlier than "high-risk" SMM. 22,30,31 In this regard, an important aspect of immune biology may be changes in spatial architecture with evolution to MM. These issues also support consideration of immune redirection therapies in this setting.…”

Section: Immune Recognition Of Premalignancy and Implications For Pre...mentioning

confidence: 99%

The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception

Dhodapkar

2022

American J Hematol

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS) are distinct disorders that likely originate in the setting of chronic immune activation. Evolution of these lesions is impacted by cross‐talk with both innate and adaptive immune systems of the host. Harnessing the immune system may, therefore, be an attractive strategy to prevent clinical malignancy. While clinical MM is characterized by both regional and systemic immune suppression and paresis, immune‐based approaches, particularly redirecting T cells have shown remarkable efficacy in MM patients. Optimal application and sequencing of these new immune therapies and their integration into clinical MM management may depend on the underlying immune status, in turn impacted by host, tumor, and environmental features. Immune therapies carry the potential to achieve durable unmaintained responses and cures in MM.

show abstract

“…For others, more conservative and sequential approaches may suffice. The concept that the hierarchy of immune exhaustion begins early also suggests the need to link immune-based prevention to early detection (155) to fully realize the potential of this strategy.…”

Section: Implications For Immune-preventionmentioning

confidence: 99%

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

McCachren

Dhodapkar

2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM), a malignant neoplasm of plasma cells that reside in the bone marrow (BM), is universally preceded by a precursor state termed monoclonal gammopathy of undetermined significance (MGUS). Many individuals with MGUS never progress to MM or progress over many years. Therefore, MGUS provides a unique opportunity to surveil changes in the BM tumor microenvironment throughout disease progression. It is increasingly appreciated that MGUS cells carry many of the genetic changes found in MM. Prior studies have also shown that MGUS cells can be recognized by the immune system, leading to early changes in the BM immune environment compared to that of healthy individuals, including alterations in both innate and adaptive immunity. Progression to clinical MM is associated with attrition of T cells with stem memory-like features and instead accumulation of T cells with more terminally differentiated features. Recent clinical studies have suggested that early application of immune-modulatory drugs, which are known to activate both innate and adaptive immunity, can delay the progression to clinical MM. Understanding the biology of how the immune response and tumors coevolve over time is needed to develop novel immune-based approaches to achieve durable and effective prevention of clinical malignancy.

show abstract

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

Cited by 6 publications

References 90 publications

Leukoplakia and Immunology: New Chemoprevention Landscapes?

Leukoplakia and Immunology: New Chemoprevention Landscapes?

The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

Contact Info

Product

Resources

About